基于活检的转录组学在临床实践中诊断抗体介导的肾移植排斥反应
该研究回顾性纳入2013至2017年间342例具有完整Banff评分的肾移植活检,评估常规兼容的分子检测对AMR诊断的影响。43例(14%)活检在组织学上未满足AMR标准但若转录组学阳性则考虑AMR,其中24例(56%)具有AMR分子特征并被重新分类为AMR;这些活检的5年死亡删失生存率与AMR组相当(P=0.22),且15例(63%)发生移植物丢失。
要点
- 常规兼容的活检转录组学可在临床实践中辅助诊断AMR。
- 14%的活检因组织学不满足AMR标准而诊断未定,其中56%经分子检测重新分类为AMR。
- 重新分类为AMR的活检移植物存活差,与明确AMR组相当。
核心结论
- 相当比例的活检可根据Banff分类从活检转录组学中获益以诊断AMR。
- 使用常规兼容的分子工具,超过一半的诊断未定活检被重新分类为AMR,且与不良移植物存活相关。
研究设计与样本
- 回顾性纳入2013至2017年间本中心所有肾移植活检,共342例具有完整Banff评分。
- 活检分为三组:已满足AMR全部Banff标准的AMR活检、未满足AMR组织学标准但转录组学阳性则考虑AMR的诊断未定活检、无排斥反应特征的控制活检。
主要发现
- 306例中43例(14%)为诊断未定AMR。
- 43例诊断未定活检中24例(56%)具有AMR分子特征并被重新分类为AMR。
- 这24例的5年死亡删失生存率与AMR组统计学等效(P=0.22),其中15例(63%)发生移植物丢失。
关键数值与推荐
- AMR诊断依据Banff分类,活检转录组学可替代部分组织学标准。
- 诊断未定AMR定义为未满足AMR组织学标准但转录组学阳性则考虑AMR。
临床怎么用
- 在临床实践中可整合常规兼容的活检转录组学检测,辅助诊断组织学不满足AMR标准的病例。
- 对组织学诊断未定的活检,转录组学结果可帮助重新分类为AMR并提示不良预后。
局限性
- 研究为单中心回顾性设计。
- 原文未报告转录组学检测的具体方法学细节及外部验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Impact of biopsy-based transcriptomics in clinical practice is still unclear. Biopsy-based transcriptomics is indicated in a significant proportion of kidney transplant biopsies for the diagnosis of antibody-mediated rejection. Biopsy-based transcriptomics is useful for antibody-mediated rejection diagnosis in clinical practice. BACKGROUND: To diagnose kidney transplant antibody-mediated rejection (AMR), biopsy-based transcriptomics can substitute for some histological criteria according to the Banff classification. However, clinical accessibility of these assays is still limited. Here, we aimed to evaluate the impact of integrating a routine-compatible molecular assay for the diagnosis of AMR in clinical practice. METHODS: All biopsies performed in our center between 2013 and 2017 were retrospectively included. These biopsies were classified into three groups: AMR biopsies which displayed the full Banff criteria of AMR independently of biopsy-based transcriptomics; undetermined for AMR biopsies which did not meet AMR histological criteria, but would have been considered as AMR if biopsy-based transcriptomics had been positive; and control biopsies which showed no features of rejection. RESULTS: Within the inclusion period, 342 biopsies had a complete Banff scoring. Thirty-six of the biopsies already met AMR criteria, and 43 of 306 (14%) were considered as undetermined for AMR. Among these biopsies, 24 of 43 (56%) had a molecular signature of AMR, reclassifying them into the AMR category. Five-year death-censored survival of these biopsies was unfavorable and statistically equivalent to that of the AMR category (P = 0.22), with 15 of 24 (63%) graft loss. CONCLUSIONS: A significant proportion of biopsies could benefit from a biopsy-based transcriptomics for AMR diagnosis according to the Banff classification. Using a routine-compatible molecular tool, more than the half of these biopsies were reclassified as AMR and associated with poor allograft survival.
引用
- Dandonneau J, François A, Bertrand D, et al. Systematic Biopsy-Based Transcriptomics and Diagnosis of Antibody-Mediated Kidney Transplant Rejection in Clinical Practice. Clin J Am Soc Nephrol. 2024. PMID: 39012712. doi:10.2215/CJN.0000000000000490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。